Bromocryptin and epimestrol in MAP-negative secondary amenorrheas.
18 patients, between 18 and 24 years of age, affected by normoprolactinemic secondary amenorrhea and still MAP-negative after three successive Epimestrol cycles underwent five cycles of a combined treatment (Bromocryptin and Epimestrol). Before and after the first cycle of combined treatment, in all patients FSH, LH, E2 and PRL were measured. Progesterone was evaluated three days after the thermic rise. The basal temperature was measured daily. In all the examined patients the combined treatment produced the appearance of the menstrual flow after the third therapeutical cycle. In 13 out of the 18 examined patients ovulation was observed. The hormonal dosage highlighted a clear increase in Gonadotropins and Estradiol levels.
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000097:blood / Q000188:drug therapy*; D001971:Bromocriptine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D004836:Epimestrol / Q000008:administration & dosage*; D004958:Estradiol / Q000097:blood; D004963:Estrenes / Q000008:administration & dosage*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D011388:Prolactin / Q000097:blood
D004963:Estrenes; D001971:Bromocriptine; D004958:Estradiol; D004836:Epimestrol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone